Porustobart (HBM4003) plus toripalimab as second-line therapy in patients with advanced hepatocellular carcinoma: a multicenter, open-label, phase I study.
Zhang N, Liu T, Luo M, Hao J, Qin S, Zhang Y, Wang G, Chen Y, Zhang J, Gu S, Niu J, Xin G, Yu G, Guo Y, Xu C, Yao J, Shen J, Xu A, Zhang S, Yang D, Gao M, Luo R, He Y, Zheng F, Cao N, Tao X.
Zhang N, et al. Among authors: xin g.
Clin Cancer Res. 2025 May 16. doi: 10.1158/1078-0432.CCR-24-3412. Online ahead of print.
Clin Cancer Res. 2025.
PMID: 40378055